Canada - Français
The Trial Assigning Individualized Options for Treatment (TAILORx) primary study group results were published in The New England Journal of Medicine
The Oncotype DX® test analyses the activity of 21 genes from the breast cancer tumour to provide an individual Recurrence Score® result, which is unique to the biology of a patient’s cancer.
The Oncotype DX test should be used when the benefit of chemotherapy for a patient is uncertain. The test increases both the patient and her doctor’s confidence in treatment decisions.
Visit these pages for further information on the Oncotype DX test, cancer-related terminology, and FAQs.